Abstract This is a case of a 55-year-old male from Bermuda whose PMH was significant for obesity and mild tobacco use, who presented to the outpatient pulmonary clinic for evaluation and consultation on two distinct RUL lung lesions. These lesions were initially discovered incidentally after the patient sustained a ground-level fall. Chest CT revealed two lung masses, one in the RUL measuring 2.8 x 3.0 cm and another in the RLL, which traversed the minor and major fissures, measuring 5.9 x 5.1 cm. PET CT revealed the RUL lesion to have an SUV max of 6.4. The RLL lesion had an SUV max of 8.2. There was also PET avidity in the right hilar region, liver, bone, and muscles. Robotic-assisted bronchoscopy with transbronchial biopsies revealed a final diagnosis of basaloid carcinoma, myoepithelial type. Introduction: Basaloid carcinoma accounts for approximately 4-5% of all lung cancers. Basaloid most commonly is a variant of squamous cell carcinoma, usually of the head and neck. Most common sites include the oropharynx, hypopharynx, supraglottic larynx, and the base of the tongue. Due to its association with squamous cell carcinoma, smoking is largely associated with basaloid carcinomas. Myoepithelial carcinomas are composed of myoepithelial cells and are most commonly seen in the salivary glands. Discussion: The basaloid carcinoma seen in this patient was not a squamous cell carcinoma but instead was a basaloid carcinoma, myoepithelial type. Basaloid and myoepithelial carcinomas are distinct entities rarely seen in combination or in the lung. Less than 0.1% of lung cancers are myoepithelial type, with only case reports and small series in the literature. Younger age and paucity of tobacco abuse make this an atypical presentation. Pathology showed monotonous epithelioid cells with canalicular-like growth pattern and focal myxoid changes. Tissue stained positive for GFAP, S100, and p40, confirming the diagnosis. Conclusion: We present a unique case of basaloid carcinoma, myoepithelial type, confirmed with histological staining. Due to its rarity, there are no standard guidelines or treatment algorithms for this cancer. This abstract is funded by: None
Lamar et al. (Fri,) studied this question.